353 related articles for article (PubMed ID: 35528835)
1.
Liu J; Shi Y; Peng D; Wang L; Yu N; Wang G; Chen W
Front Cardiovasc Med; 2022; 9():842980. PubMed ID: 35528835
[TBL] [Abstract][Full Text] [Related]
2. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms.
Rodriguez-Ramiro I; Vauzour D; Minihane AM
Proc Nutr Soc; 2016 Feb; 75(1):47-60. PubMed ID: 26592314
[TBL] [Abstract][Full Text] [Related]
3. New targets for NAFLD.
Parlati L; Régnier M; Guillou H; Postic C
JHEP Rep; 2021 Dec; 3(6):100346. PubMed ID: 34667947
[TBL] [Abstract][Full Text] [Related]
4. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD.
Du X; Cai C; Yao J; Zhou Y; Yu H; Shen W
Biochem Biophys Res Commun; 2017 Jan; 483(1):409-417. PubMed ID: 28027934
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
6. A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets.
Hong M; Li S; Wang N; Tan HY; Cheung F; Feng Y
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335383
[No Abstract] [Full Text] [Related]
7. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.
Higuchi N; Kato M; Shundo Y; Tajiri H; Tanaka M; Yamashita N; Kohjima M; Kotoh K; Nakamuta M; Takayanagi R; Enjoji M
Hepatol Res; 2008; 38(11):1122-9. PubMed ID: 18684130
[TBL] [Abstract][Full Text] [Related]
8. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
10. Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype.
Shen L; Cui A; Xue Y; Cui Y; Dong X; Gao Y; Yang H; Fang F; Chang Y
J Biol Chem; 2014 Aug; 289(34):23332-42. PubMed ID: 24993831
[TBL] [Abstract][Full Text] [Related]
11. Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis.
Peng A; Liu S; Fang L; Zhu Z; Zhou Y; Yue S; Ma Z; Liu X; Xue S; Qiu Y; Qi R
Eur J Pharmacol; 2022 Apr; 921():174841. PubMed ID: 35278405
[TBL] [Abstract][Full Text] [Related]
12. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway.
Jin SS; Lin CJ; Lin XF; Zheng JZ; Guan HQ
Ann Hepatol; 2022; 27(2):100584. PubMed ID: 34808393
[TBL] [Abstract][Full Text] [Related]
13. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
14. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
15. Effects of the aqueous extract from Salvia miltiorrhiza Bge on the pharmacokinetics of diazepam and on liver microsomal cytochrome P450 enzyme activity in rats.
Jinping Q; Peiling H; Yawei L; Abliz Z
J Pharm Pharmacol; 2003 Aug; 55(8):1163-7. PubMed ID: 12956908
[TBL] [Abstract][Full Text] [Related]
16. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.
Liu Y; Xu W; Zhai T; You J; Chen Y
Acta Pharm Sin B; 2019 Jul; 9(4):745-757. PubMed ID: 31384535
[TBL] [Abstract][Full Text] [Related]
17. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
[TBL] [Abstract][Full Text] [Related]
18. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
Zhou H; Ma C; Wang C; Gong L; Zhang Y; Li Y
Eur J Pharmacol; 2021 May; 898():173976. PubMed ID: 33639194
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
20. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).
Ahmed MH; Byrne CD
Drug Discov Today; 2007 Sep; 12(17-18):740-7. PubMed ID: 17826687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
